Skip to main content

Table 4 Predictive factors for 2-year disease-free survival rate and grade III or IV toxicity in patients with gastric cancer who underwent adjuvant TS-1 treatment

From: Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment

Variables 2-year disease-free survival rate P Grade III or IV toxicity n (%) P
Gender Male (n = 24) 75% 0.68 6 (25.0) 0.33
Female (n = 16) 74% 2 (12.5)
Age ≥65 (n = 13) 82% 0.29 1 (7.7) 0.18
<65 (n = 27) 50% 7 (25.9)
Histological type Diffuse type (n = 25) 74% 0.57 6 (24.0) 0.41
Intestinal type (n = 15) 75% 2 (13.3)
ECOG performance status scale 0 (n = 32) 74% 0.63 6 (18.8) 0.74
1 to 2 (n = 8) 75% 2 (25.0)
Type of gastrectomy Total (n = 15) 72% 0.66 6 (40.0) 0.014
Subtotal (n = 25) 76% 2 (8.0)
T stage 1 to 2 (n = 28) 82% 0.44 6 (21.4) 0.73
3 to 4 (n = 12) 75% 2 (16.7)
Lymph node metastases numbers 0 to 15 (n = 34) 91% <0.001 0 (0) 0.18
>15 (n = 6) 17% (HR 0.09, 95% CI 0.02, 0.40) 8 (23.5)
  1. CI: confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.